Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Debled

Showing results (61-70 of 100) with videos related to

Pageof 10
Sort By:
BMC Medical Genomics|November 29, 2012
An array CGH based genomic instability index (G2I) is predictive of clinical outcome in breast cancer and reveals a subset of tumors without lymph node involvement but with poor prognosisFrançoise Bonnet, Mickael Guedj, Natalie Jones, et al.
Clinical Pharmacology and Therapeutics|February 21, 2019
Factors Affecting Tamoxifen Metabolism in Patients With Breast Cancer: Preliminary Results of the French PHACS StudyAlicja Puszkiel, Cécile Arellano, Christelle Vachoux, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 6, 2017
Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 StudySigne Borgquist, Anita Giobbie-Hurder, Thomas P Ahern, et al.
Breast Cancer Research and Treatment|March 29, 2023
Pattern and risk factors of isolated local relapse among women with hormone receptor-positive and HER2-negative breast cancer and lymph node involvement: 10-year follow-up analysis of the PACS 01 and PACS 04 trialsElie Rassy, Thomas Filleron, Alessandro Viansone, et al.
The Lancet. Oncology|June 15, 2013
6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trialXavier Pivot, Gilles Romieu, Marc Debled, et al.
British Journal of Cancer|July 15, 2015
Clinical and genomic analysis of a randomised phase II study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally advanced hormone-receptor-positive breast cancerNathalie Quenel-Tueux, Marc Debled, Justine Rudewicz, et al.
Clinical Pharmacology and Therapeutics|October 13, 2020
Model-Based Quantification of Impact of Genetic Polymorphisms and Co-Medications on Pharmacokinetics of Tamoxifen and Six Metabolites in Breast CancerAlicja Puszkiel, Cécile Arellano, Christelle Vachoux, et al.
Pharmaceuticals (Basel, Switzerland)|November 26, 2020
VEGF-Related Germinal Polymorphisms May Identify a Subgroup of Breast Cancer Patients with Favorable Outcome under Bevacizumab-Based Therapy-A Message from COMET, a French Unicancer Multicentric StudyJocelyn Gal, Gérard Milano, Patrick Brest, et al.
Breast Cancer (Tokyo, Japan)|January 11, 2023
Clinical outcome of patients with isolated central nervous system progression on first-line pertuzumab and trastuzumab treatment for HER2-positive metastatic breast cancer in a real-life cohortLaetitia Collet, Lauriane Eberst, Gauthier Ludovic, et al.
European Journal of Cancer (Oxford, England : 1990)|May 15, 2017
Optimal duration of adjuvant chemotherapy for high-risk node-negative (N-) breast cancer patients: 6-year results of the prospective randomised multicentre phase III UNICANCER-PACS 05 trial (UCBG-0106)Pierre Kerbrat, Isabelle Desmoulins, Lise Roca, et al.
Pageof 10

Showing results (61-70 of 100) with videos related to

Sort By:
Pageof 10
BMC Medical Genomics|November 29, 2012
An array CGH based genomic instability index (G2I) is predictive of clinical outcome in breast cancer and reveals a subset of tumors without lymph node involvement but with poor prognosisFrançoise Bonnet, Mickael Guedj, Natalie Jones, et al.
Clinical Pharmacology and Therapeutics|February 21, 2019
Factors Affecting Tamoxifen Metabolism in Patients With Breast Cancer: Preliminary Results of the French PHACS StudyAlicja Puszkiel, Cécile Arellano, Christelle Vachoux, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 6, 2017
Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 StudySigne Borgquist, Anita Giobbie-Hurder, Thomas P Ahern, et al.
Breast Cancer Research and Treatment|March 29, 2023
Pattern and risk factors of isolated local relapse among women with hormone receptor-positive and HER2-negative breast cancer and lymph node involvement: 10-year follow-up analysis of the PACS 01 and PACS 04 trialsElie Rassy, Thomas Filleron, Alessandro Viansone, et al.
The Lancet. Oncology|June 15, 2013
6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trialXavier Pivot, Gilles Romieu, Marc Debled, et al.
British Journal of Cancer|July 15, 2015
Clinical and genomic analysis of a randomised phase II study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally advanced hormone-receptor-positive breast cancerNathalie Quenel-Tueux, Marc Debled, Justine Rudewicz, et al.
Clinical Pharmacology and Therapeutics|October 13, 2020
Model-Based Quantification of Impact of Genetic Polymorphisms and Co-Medications on Pharmacokinetics of Tamoxifen and Six Metabolites in Breast CancerAlicja Puszkiel, Cécile Arellano, Christelle Vachoux, et al.
Pharmaceuticals (Basel, Switzerland)|November 26, 2020
VEGF-Related Germinal Polymorphisms May Identify a Subgroup of Breast Cancer Patients with Favorable Outcome under Bevacizumab-Based Therapy-A Message from COMET, a French Unicancer Multicentric StudyJocelyn Gal, Gérard Milano, Patrick Brest, et al.
Breast Cancer (Tokyo, Japan)|January 11, 2023
Clinical outcome of patients with isolated central nervous system progression on first-line pertuzumab and trastuzumab treatment for HER2-positive metastatic breast cancer in a real-life cohortLaetitia Collet, Lauriane Eberst, Gauthier Ludovic, et al.
European Journal of Cancer (Oxford, England : 1990)|May 15, 2017
Optimal duration of adjuvant chemotherapy for high-risk node-negative (N-) breast cancer patients: 6-year results of the prospective randomised multicentre phase III UNICANCER-PACS 05 trial (UCBG-0106)Pierre Kerbrat, Isabelle Desmoulins, Lise Roca, et al.
Pageof 10